Overview

A class action lawsuit has been filed against ASP Isotopes, Inc. (“ASP Isotopes” or the “Company”) (NASDAQ: ASPI) and certain of the Company’s former senior executive officers alleging violations of the federal securities laws.  The ASP Isotopes class action lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired ASP Isotopes securities between October 30, 2024, and November 26, 2024, both dates inclusive (the “Class Period”).  Investors have until February 3, 2025, to seek appointment as lead plaintiff in the ASP Isotopes class action lawsuit.

ASP Isotopes is a development stage advanced materials company focused on the production, enrichment, and sale of isotopes.  The Company purports to have multiple isotope enrichment plants currently under development in South Africa.  The Company is engaged in the development of “quantum enrichment technology” which allegedly uses lasers to produce enriched isotopes, including Uranium-235.  The Company purports to be in development of high-assay low-enriched uranium (“HALEU”) reactors to be fueled by Uranium-235 produced using its quantum enrichment technology.

The Company states that its HALEU facilities could be deployed for considerably lower capital costs, and in much less time, compared to the construction of an enrichment facility using a traditional centrifuge process.  The Company has two operating segments: (i) nuclear fuels, and (ii) specialist isotopes and related services.  The Company’s nuclear fuels operating segment is primarily operated through its Quantum Leap Energy subsidiary.

On October 30, 2024, the Company announced it had entered into a term sheet with TerraPower, LLC related to the construction of a uranium enrichment facility capable of producing HALEU and the future supply of HALEU to TerraPower.

The ASP Isotopes class action lawsuit alleges that Defendants, throughout the Class Period, provided materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations, and prospects to make the statements made, in light of the circumstances under which they were made, not false and misleading.  Specifically, Defendants failed to disclose that: (1) the Company overstated the potential effectiveness of its enrichment technology; (2) the Company overstated the development potential of its HALEU; (3) the Company overstated its nuclear fuels operating segment results; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

*          *          *

If you purchased or otherwise acquired ASP Isotopes securities between October 30, 2024, and November 26, 2024, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at [email protected]. 

The deadline to apply to the Court to serve as lead plaintiff in the ASP Isotopes class action lawsuit is February 3, 2025.